Efficacy of Extended Release Tramadol for Treating Prescription Opioid Withdrawal
NCT ID: NCT00980044
Last Updated: 2017-04-05
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2/PHASE3
53 participants
INTERVENTIONAL
2009-10-31
2012-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Medications Development for Drug Abuse Disorders
NCT01188421
Addition of Naltrexone to Methadone Taper
NCT00135759
5HT3 Antagonists to Treat Opioid Withdrawal and to Prevent the Progression of Physical Dependence
NCT01549652
Treatment of Withdrawal Symptoms and Prevention of Relapse in Patients With Tramadol Abuse
NCT05569031
Effects of Buprenorphine/Naloxone Administered in Different Ways For Treating Opioid Dependence
NCT00134914
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Tramadol 200 mg then placebo
Tramadol 200 mg daily for 1 week then placebo given for 1 week
Tramadol
Oral Medication
Placebo for two weeks
Medication
Placebo
Oral Medication
Tramadol 600 mg then placebo
Tramadol 600 mg daily given for 1 week given then placebo given for 1 week
Tramadol
Oral Medication
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tramadol
Oral Medication
Placebo
Oral Medication
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute on Drug Abuse (NIDA)
NIH
Michelle Lofwall
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Michelle Lofwall
Principal Investigatory
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Michelle Lofwall, M.D.
Role: PRINCIPAL_INVESTIGATOR
University of Kentucky
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Kentucky
Lexington, Kentucky, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Lofwall MR, Babalonis S, Nuzzo PA, Siegel A, Campbell C, Walsh SL. Efficacy of extended-release tramadol for treatment of prescription opioid withdrawal: a two-phase randomized controlled trial. Drug Alcohol Depend. 2013 Nov 1;133(1):188-97. doi: 10.1016/j.drugalcdep.2013.05.010. Epub 2013 Jun 4.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
09-0489
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.